Levels of exhausted CD8+ T cells were evaluated based on the work of Milner et al., who used a B16-GP32 model that demonstrated decreased exhaustion of tumor antigen–specific CD8+ T cells following BRD4 inhibition with JQ1 (39). The gene discussed is BRD4; the disease is neoplasm.